About Keryx

Board of Directors

Our board of directors and management team embody our vision for nurturing the development of our medicine and delivering value to our company. Each member brings extensive experience and expertise in the fields of pharmaceuticals, finance, and governance. You can view the bios of the team below.

Kevin J. Cameron, Board Member

Mr. Cameron joined the Board in April 2007, bringing with him more than 10 years of corporate governance and strategy experience. In 2003, Mr. Cameron co-founded and currently serves as Chairman of the Policy Advisory Board of Glass Lewis & Company, a leading independent research firm focused on issues of corporate governance. From 2001 to 2002, Mr. Cameron handled corporate affairs for Moxi Digital, a technology venture focused on digital entertainment. From 1997 to 2001, he was employed by NorthPoint Communications, a publicly traded broadband telecommunications company. Prior to 1997, Mr. Cameron was an attorney with the corporate law firm of Kellogg, Huber, Hansen, Todd & Evans in Washington, DC, and served as a law clerk to the Hon. James L. Buckley of the United States Court of Appeals for the District of Columbia Circuit. Mr. Cameron earned a law degree from the University of Chicago and an undergraduate degree from McGill University.

Mark J. Enyedy, Board Member

Mr. Enyedy joined the Board in September 2017, bringing more than 25 years of combined general management, business development, and legal experience in the biotechnology industry across multiple therapeutic areas. He currently serves as president and chief executive officer of ImmunoGen, Inc., a position he has held since 2016. Prior to ImmunoGen, Mr. Enyedy served as executive vice president and head of corporate development for Shire plc leading the company’s strategy, merger and acquisitions,, and corporate planning functions and providing commercial oversight for the company’s pre-Phase 3 portfolio. Previously, Mr. Enyedy served as chief executive officer of Proteostasis Therapeutics, Inc., following 15 years at Genzyme Corporation in diverse roles, and president of the transplant, oncology, and multiple sclerosis divisions. Before joining Genzyme, Mr. Enyedy was an associate with the law firm Palmer & Dodge. He holds a J.D. from Harvard Law School and a B.S. from Northeastern University. Mr. Enyedy also serves on the board of directors of Fate Therapeutics.

Steven C. Gilman, Ph.D., Board Member

Dr. Gilman joined the Board in April 2016 and brings more than 28 years of scientific and development expertise in the healthcare industry. Dr. Gilman served most recently as chief scientific officer of Cubist Pharmaceuticals until its acquisition by Merck & Co. Prior to joining Cubist, he served as chairman of the Board of Directors and chief executive officer of ActivBiotics, a privately held biopharmaceutical company. Previously, Dr. Gilman worked at Millennium Pharmaceuticals, Inc., where he held a number of senior leadership roles including vice president and general manager of Inflammation. Prior to Millennium, he was group director at Pfizer Global Research and Development, where he was responsible for drug discovery of several therapeutic areas, including immunology and antibacterials. Dr. Gilman has also held scientific, business, and academic appointments at Wyeth, Cytogen Corporation, Temple Medical School, and Connecticut College. He currently serves as Chairman and  CEO of ContraFect Corporation (Nasdaq:CFRX) and on the board of directors of Vericel (Nasdaq:VCEL), SCYNEXIS (Nasdaq:SCYX), the Massachusetts Biotechnology Association, the Northeastern University Drug Discovery Advisory Board and the Penn State University Biotechnology Advisory Board. Dr. Gilman received his M.S. and Ph.D. degrees in microbiology from Pennsylvania State University, his post-doctoral training at Scripps Clinic and Research Foundation, and received a B.A. in microbiology from Miami University of Ohio.

Michael T. Heffernan, Board Member

Mr. Heffernan has more than 25 years of experience in the pharmaceutical and related healthcare industries. He is currently the founder, president and CEO of Collegium Pharmaceutical, Inc. Prior to Collegium, he was the founder, president and CEO of Onset Dermatologics, a dermatology focused company that was spun out of Collegium to create PreCision Dermatology, which was acquired by Valeant (2014). Mr. Heffernan held prior positions as co-founder, president and CEO of Clinical Studies Ltd., a pharmaceutical contract research organization that was acquired by PhyMatrix Corp. and later served as president and CEO of PhyMatrix. Mr. Heffernan began his career at Eli Lilly and Company and served in numerous sales and marketing roles. Mr. Heffernan is currently the chairman of the board for Veloxis Pharmaceuticals. Mr. Heffernan earned his B.S. Degree in Pharmacy from the University of Connecticut and is a Registered Pharmacist.

Greg Madison, Chief Executive Officer and Board Member

Greg Madison, currently the Company’s Chief Executive Officer, joined the Company in February 2014, and was appointed to its Board of Directors on March 10, 2015. Mr. Madison has more than 20 years of experience in the US pharmaceutical industry. Mr. Madison previously served as Executive Vice President and Chief Commercial Officer of AMAG Pharmaceuticals (AMAG), where in 2013, he led the team to significant growth in net revenues. Prior to AMAG, Mr. Madison spent 12 years at Genzyme/Sanofi developing extensive commercial and general management expertise as he progressed into roles of increasing responsibilities and leadership, culminating in his most recent role as Vice President and General Manager of the Renal division. In this role, Mr. Madison led a global organization with three marketed products with combined revenues exceeding $1 billion. He holds a Bachelor of Business Administration in Finance from the University of Massachusetts, Amherst.

Jodie Morrison, Board Member

Ms. Morrison has 20 years of broad experience in the pharmaceutical and biotech industries, including extensive operational and development leadership. From 2006 to 2017, Ms. Morrison held positions of increasing responsibility at Tokai Pharmaceuticals, including serving her last 4 years as president and chief executive officer and a member of its board of directors. Prior to being appointed CEO, she served as Tokai’s chief operating officer and head of clinical affairs. Throughout her tenure at Tokai she oversaw the company’s development pipeline and led it’s operational management, including the execution of the $105M IPO and completion of the merger forming Novus Therapeutics in 2017. Prior to joining Tokai, Ms. Morrison was director of clinical operations and medical affairs at Dyax Corporation where she built and led the clinical development teams for the Kalbitor™ (hereditary angioedema) program. Before joining Dyax, she held clinical management positions at Curis, Inc. and Diacrin, Inc. Ms. Morrison has a B.A. in neuroscience from Mount Holyoke College, business training from the Greater Boston Executive Program at MIT Sloan School of Management and clinical research certification from Boston University School of Medicine.  In addition to her appointment at Keryx, Ms. Morrison currently sits on the board of directors for Aileron Therapeutics (ALRN) and Novus Therapeutics (NVUS).

Daniel P. Regan, Board Member

Daniel P. Regan has broad pharmaceutical leadership experience across the spectrum of global commercialization, sales, and marketing of novel therapies for the treatment of chronic kidney disease. From 1999 to 2011, Mr. Regan held positions of increasing responsibility at Genzyme/Sanofi, leading multi-functional teams in sales, marketing, and commercialization of renal products. Mr. Regan’s career at Genzyme included his appointment as Global General Manager, Senior Vice President of the Renal franchise, with direct responsibility for all aspects of worldwide renal commercial operations, including the Renagel®/Renvela® phosphate binder franchise and the worldwide launch of Renvela®, growing the renal franchise to global revenue approaching $1 billion. From 2011 to 2012, Mr. Regan served as Chief Commercial Officer of Inspiration Biopharmaceuticals, which sold its main asset to Baxter International. Most recently, from 2012 until 2015, Mr. Regan was Chief Commercial Officer of Intercept Pharmaceuticals. Mr. Regan has a B.A. in Economics from the University of Massachusetts.

Michael Rogers, Chairman

Mr. Rogers joined the Board in April 2016 bringing to Keryx more than 25 years of financial leadership in the biotech industry. He is currently chief financial officer of Aerpio Pharmaceuticals Inc. Prior to Aerpio, Mr. Rogers was chief financial officer of Acorda Therapeutics from 2013 to 2016. He was chief financial officer of four additional healthcare companies: BG Medicine, Inc., Indevus Pharmaceuticals, Inc., Advanced Health Corporation and Autoimmune Inc. Prior to his roles as CFO, Mr. Rogers was an investment banker at Lehman Brothers and PaineWebber, where he focused on life sciences companies. Mr. Rogers received his B.A. from Union College and an M.B.A. from the Darden School of Business at the University of Virginia. He currently serves on the Board of Directors for pSivida Corp.

Share this page
12/17 PP-AUR-US-0542

You are leaving www.keryx.com.

You are leaving www.keryx.com, a website of Keryx Biopharmaceuticals, Inc. Keryx does not review or control the content of non-Keryx websites, and this hyperlink does not constitute an endorsement by Keryx of the site’s content. Keryx’s privacy procedures do not apply to the owners of a non-Keryx website.